Investing.com - Adaptimmune Therapeutics reported on Friday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.040 on revenue of $7.01M. Analysts polled by Investing.com anticipated EPS of $-0.279 on revenue of $6.3M (NYSE:MMM).
Adaptimmune Therapeutics shares are down 34.93% from the beginning of the year and are trading at $2.440 , down-from-52-week-high.
Adaptimmune Therapeutics shares gained 9.91% in intra-day trade the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar